BR112022013418A2 - Composição para uso na prevenção e/ou no tratamento de cardiotoxicidade, e, preparação combinada - Google Patents
Composição para uso na prevenção e/ou no tratamento de cardiotoxicidade, e, preparação combinadaInfo
- Publication number
- BR112022013418A2 BR112022013418A2 BR112022013418A BR112022013418A BR112022013418A2 BR 112022013418 A2 BR112022013418 A2 BR 112022013418A2 BR 112022013418 A BR112022013418 A BR 112022013418A BR 112022013418 A BR112022013418 A BR 112022013418A BR 112022013418 A2 BR112022013418 A2 BR 112022013418A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- inhibitors
- prevention
- treatment
- combined preparation
- Prior art date
Links
- 206010048610 Cardiotoxicity Diseases 0.000 title abstract 2
- 231100000259 cardiotoxicity Toxicity 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000001630 malic acid Substances 0.000 abstract 1
- 235000011090 malic acid Nutrition 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 239000002525 vasculotropin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USOS DE UMA COMPOSIÇÃO E DE UMA PREPARAÇÃO COMBINADA. Trata-se de uma composição para uso na prevenção e/ou no tratamento de cardiotoxicidade induzida por pelo menos um agente quimioterápico em um indivíduo que passa por quimioterapia, sendo que a composição compreende um agente ativo, sendo que o dito agente ativo contém os aminoácidos leucina, isoleucina, valina, treonina, lisina e ácido cítrico, ácido succínico, ácido málico. O dito agente quimioterápico pode ser selecionado no grupo que consiste em antraciclinas, inibidores de HER2/ErbB2, inibidores de tirosina-quinase, inibidores de fator de crescimento endotelial vascular, inibidores de ponto de verificação imunológico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000000442A IT202000000442A1 (it) | 2020-01-13 | 2020-01-13 | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
| PCT/IB2020/062291 WO2021144639A1 (en) | 2020-01-13 | 2020-12-21 | Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013418A2 true BR112022013418A2 (pt) | 2022-09-20 |
Family
ID=70009337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013418A BR112022013418A2 (pt) | 2020-01-13 | 2020-12-21 | Composição para uso na prevenção e/ou no tratamento de cardiotoxicidade, e, preparação combinada |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230067642A1 (pt) |
| EP (1) | EP3848025B9 (pt) |
| JP (1) | JP2023509627A (pt) |
| KR (1) | KR20220128629A (pt) |
| CN (1) | CN114980878A (pt) |
| AU (1) | AU2020423611A1 (pt) |
| BR (1) | BR112022013418A2 (pt) |
| CA (1) | CA3166643A1 (pt) |
| CL (1) | CL2022001780A1 (pt) |
| ES (1) | ES2954594T3 (pt) |
| IT (1) | IT202000000442A1 (pt) |
| MX (1) | MX2022008096A (pt) |
| PL (1) | PL3848025T3 (pt) |
| WO (1) | WO2021144639A1 (pt) |
| ZA (1) | ZA202207728B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| CN113425707B (zh) * | 2021-07-30 | 2022-12-30 | 青岛大学附属医院 | 壬二酸预防蒽环类抗肿瘤药物心肌毒性的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITTO20030789A1 (it) | 2003-10-07 | 2005-04-08 | Professional Dietetics Srl | Composizione a base di amino acidi per il trattamento |
| EP2676664B1 (en) * | 2011-02-17 | 2017-06-21 | EA Pharma Co., Ltd. | Potentiator of antitumor activity of chemotherapeutic agent |
| WO2012147901A1 (ja) * | 2011-04-28 | 2012-11-01 | 味の素株式会社 | 抗癌剤副作用改善用組成物 |
| US20160038565A1 (en) * | 2012-06-15 | 2016-02-11 | Gencia Corporation | Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy |
| PL3294279T3 (pl) * | 2015-05-14 | 2020-06-29 | Professional Dietetics International S.R.L. | Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii |
| US20180344677A1 (en) * | 2015-11-27 | 2018-12-06 | Doublegood Ab | Food supplement and composition for treating the metabolic syndrome |
| IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
-
2020
- 2020-01-13 IT IT102020000000442A patent/IT202000000442A1/it unknown
- 2020-12-21 KR KR1020227025981A patent/KR20220128629A/ko active Search and Examination
- 2020-12-21 EP EP20216079.2A patent/EP3848025B9/en active Active
- 2020-12-21 WO PCT/IB2020/062291 patent/WO2021144639A1/en active Application Filing
- 2020-12-21 JP JP2022540340A patent/JP2023509627A/ja active Pending
- 2020-12-21 CN CN202080093098.3A patent/CN114980878A/zh active Pending
- 2020-12-21 MX MX2022008096A patent/MX2022008096A/es unknown
- 2020-12-21 PL PL20216079.2T patent/PL3848025T3/pl unknown
- 2020-12-21 US US17/792,380 patent/US20230067642A1/en active Pending
- 2020-12-21 AU AU2020423611A patent/AU2020423611A1/en active Pending
- 2020-12-21 ES ES20216079T patent/ES2954594T3/es active Active
- 2020-12-21 CA CA3166643A patent/CA3166643A1/en active Pending
- 2020-12-21 BR BR112022013418A patent/BR112022013418A2/pt unknown
-
2022
- 2022-06-29 CL CL2022001780A patent/CL2022001780A1/es unknown
- 2022-07-12 ZA ZA2022/07728A patent/ZA202207728B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3848025B9 (en) | 2023-08-16 |
| EP3848025B1 (en) | 2023-06-07 |
| US20230067642A1 (en) | 2023-03-02 |
| JP2023509627A (ja) | 2023-03-09 |
| EP3848025C0 (en) | 2023-06-07 |
| EP3848025A1 (en) | 2021-07-14 |
| CL2022001780A1 (es) | 2023-02-03 |
| KR20220128629A (ko) | 2022-09-21 |
| ZA202207728B (en) | 2023-04-26 |
| ES2954594T3 (es) | 2023-11-23 |
| IT202000000442A1 (it) | 2021-07-13 |
| PL3848025T3 (pl) | 2023-10-30 |
| WO2021144639A1 (en) | 2021-07-22 |
| CN114980878A (zh) | 2022-08-30 |
| CA3166643A1 (en) | 2021-07-22 |
| MX2022008096A (es) | 2022-07-27 |
| AU2020423611A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013418A2 (pt) | Composição para uso na prevenção e/ou no tratamento de cardiotoxicidade, e, preparação combinada | |
| AR111455A1 (es) | Formulación estable de anticuerpo | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| BR112022016220A2 (pt) | Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| PE20211202A1 (es) | Composiciones de glp-1 y sus usos | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| CO2019011463A2 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas | |
| UY37149A (es) | 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas | |
| AR085397A1 (es) | Combinacion de inhibidores de quinasa y sus usos | |
| BR112018067597A2 (pt) | célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit | |
| CL2021001536A1 (es) | 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden | |
| BR112022012474A2 (pt) | Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes. | |
| CL2022000471A1 (es) | Péptido q-er | |
| CL2020003015A1 (es) | Conversión a escala preparativa de goniautoxinas en neosaxitoxina | |
| EA202092749A1 (ru) | Композиции, содержащие аминокислоты, для применения в предотвращении и лечении заболеваний печени | |
| Mendes-Silverio et al. | Activation of soluble guanylyl cyclase with inhibition of multidrug resistance protein inhibitor-4 (MRP4) as a new antiplatelet therapy | |
| BR112017022506A2 (pt) | composições compreendendo aminoácidos para uso no tratamento de mucosites em pacientes com neoplasia submetidos a terapia de radiação e / ou quimioterapia | |
| AR117707A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR113145A1 (es) | Composiciones y métodos para mejorar la utilización de nitrógeno en un rumiante | |
| BR112023000654A2 (pt) | Composto de pirazolopirimidina usado como inibidor de atr quinase | |
| BR112022013204A2 (pt) | Usos de uma composição e de uma preparação combinada | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk | |
| AR118853A1 (es) | Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |